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To the Editor: The title of the study by Davenport et al.1
seems to imply a causal link between achieving blood
pressure (BP) targets during dialysis and increasing the
frequency of intradialytic hypotension (IDH). The authors
point out that an important cause of both IDH and lower
predialysis BP may be underlying cardiac disease. It appears
that the same facts may explain some of their observations.
Patients in their survey who experienced IDH were those who
more often achieved postdialysis BP targets. Patients who achieved
postdialysis BP targets were often not treated with antihyperten-
sive drugs. Thus, the latter patients may well have had cardiac
or other diseases that lower BP, precluding the need for anti-
hypertensive drugs. It would follow that IDH was experienced not
because of attempts to control BP but because of the
predisposition of the patient to IDH. The authors found no
direct relationship between antihypertensive drug use and episodes
of IDH, which further supports an absence of a causal link
between treatment of hypertension and the appearance of IDH.
Predialysis and postdialysis BP measurements are poor
surrogates of interdialytic ambulatory BP and guidelines based
on predialysis and postdialysis BP are based on few data.2 Home
BP recordings correlate better with ambulatory BP recordings,3
left ventricular hypertrophy4 and mortality in hemodialysis
patients5 compared with predialysis or postdialysis BP. Without
studying the problem of hypertension in hemodialysis patients
with more ecologically valid BP recordings, it would be
premature and potentially dangerous to abandon attempts to
control this important cardiovascular risk factor.6
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Although there is a robust correlation between blood
pressure and the risk of stroke, and a ‘J’-shaped association
with myocardial infarction in the general population,1,2 the
situation is less clear-cut in the hemodialysis population,
particularly when pre- and/or post-hemodialysis blood
pressure recordings are analyzed. This paradox could
either be due to a difference in the impact of blood
pressure control on cardiovascular risk between hemo-
dialysis patients and the general population, or that the
apparent lack of association is due to pre- and post-
hemodialysis blood pressure recordings not being repre-
sentative of blood pressure control.
A recent prospective study reported that survival of
hemodialysis patients was increased in those patients who
met the current KDOQI clinical guideline recommenda-
tions.2 However, when the impact of individual guideline
recommendations was analyzed, although there was a
positive effect on survival when guideline-recommended
target range of Kt/V, albumin, calcium, phosphorus, and
PTH was achieved, survival was reduced in those patients
who achieved the post-hemodialysis blood pressure target.
Although some patients, who achieved the KDOQI and UK
Renal Association post-hemodialysis blood pressure target,
undoubtedly had poor cardiac function, this was not
universally the case. It is now realized that intradialytic
hypotension can potentially lead to myocardial stunning,
as cardiac perfusion depends on the diastolic blood
pressure.3 Repeated episodes of intradialytic hypotension
may therefore be deleterious and result in increased
patient death in the hemodialysis cohort.4
Professor Agarwal has published extensively over the
last few years, demonstrating that pre- and post-hemodia-
lysis blood pressure recordings may not accurately
represent blood pressure control in this group of patients.
Our own data support his contention.5 Unfortunately,
current North American and UK guidelines recommend
blood pressure targets in hemodialysis patients based
solely on pre- and/or post-hemodialysis blood pressure
recordings. If these recordings do not accurately reflect
blood pressure control in this group of patients, then this
may partially explain the differences observed with regard
to blood pressure control and cardiovascular and cerebro-
vascular mortality compared to the general population.
Thus, wherever possible, guideline recommendations
should be based on firm evidence. Recurrent episodes of
intradialytic hypotension6 in an attempt to achieve the
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post-hemodialysis target blood pressure7 may therefore
paradoxically decrease life expectancy rather than prolong
it.
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To the Editor: Hallelujah! The long anticipated results of the
Dialysis Clinical Outcomes Revisited (DCOR) trial are finally
published.1 To our surprise, despite triumphant press releases
and hyperbolic pronouncements made in industry-sponsored
symposia at nephrology meetings 2 years ago, the DCOR
study actually found no mortality benefit among hemodia-
lysis patients treated with sevelamer as compared with
patients treated with CCPBs (calcium-containing phosphate
binders). At once, the NKF-KDOQI/KDIGO opinion-based
recommendations regarding the possible advantages of the
non-calcium, non-aluminum resin-based phosphate binder,
sevelamer become moot. In these guidelines, the postulated
rationale for preferential use of non-calcium binders in
certain clinical circumstances was based on observational
studies showing an association between the use of CCPB
and mortality risk or intervention trials employing surrogate
end points such as cardiovascular calcification.2,3 These
important results from DCOR imply that clinicians can now
confidently prescribe effective and substantially less expensive
CCPB therapy unburdened by prior expert ‘opinion’
suggesting that CCPBs represent arcane and potentially
cardiotoxic therapy. Case closed, right? Well probably not.
Although statistically invalid given the negative results for the
primary outcomes (all-cause and cardiovascular mortality),
the authors conducted a post hoc analysis to study the effect
of patient age on the results. A major case is made for a
possible benefit on all-cause mortality in subjects aged over
65 years treated with sevelamer. This post hoc analysis will
undoubtedly become fodder for pharmaceutical company
marketing and quite possibly will be used to justify additional
opinion-based recommendations for preferential use of
sevelamer in the older dialysis patient population. However,
we are quite concerned about incomplete reporting of the
results of the DCOR study. The reported dropout rate (49%)
is extremely high and unacceptable given the simplicity of the
DCOR study design. DCOR is a mortality study that enrolled
only Medicare-eligible dialysis patients. Although study
subjects may withdraw consent for participation, an intent-
to-treat analysis of all enrolled subjects is feasible, as there
are only three possible outcomes regarding mortality (alive
on dialysis, alive after kidney transplant, or dead). Although
data are not reported, the authors mention that an intent-
to-treat analysis of all-cause mortality employing the Centers
for Medicare and Medicaid Services (CMS) database also
showed no difference in all-cause mortality. Did the
postulated age-related difference in mortality persist in this
intent-to-treat data set? Full reporting of intent-to-treat data
analysis should have been a prerequisite for publication and
remains mandatory for any meaningful analysis of DCOR
results.
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The case against calcium-based binders has been accumu-
lating for years.1 The presence, and extent, of vascular
calcifications are strong predictors of cardiovascular and
all-cause mortality.2,3 The dose of calcium-based phosphate
binders (acetate or carbonate) has been linked to the
severity of vascular calcification.2,4 As a result of these
observations, the US National Kidney Foundation had
issued guidelines calling for lower serum phosphorus and
calcium targets in dialysis patients, limitation of the dose
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